Immunomodulator for the management of human immunodficiency virus (hiv) disease/infection

摘要

Human Immunodeficiency virus causes depletion of CD 4 cells. The depletion of CD 4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs. These drugs have their own side effects and immune reconstitution achieved is delayed and slow. Various attempts have been made to improve CD 4 count, use of IL-2 is one of them. It is associated with systemic side effects during the period of its administration. The present invention provides immunomodulator based on Mycobacterium w. Its use in associated with symptomatic improvement as well as improvement in immunity as evidenced by improved CD 4 count in HIV infected individuals.